Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library

被引:66
作者
Dotor, Javier
Lopez-Vazquez, Ana B.
Lasarte, Juan J.
Sarobe, Pablo
Garcia-Granero, Marta
Riezu-Boj, Jose I.
Martinez, Alfonso
Feijoo, Esperanza
Lopez-Sagaseta, Jacinto
Hermida, Jose
Prieto, Jesus
Borras-Cuesta, Francisco
机构
[1] Univ Navarra, Ctr Appl Med Res, Div Hepatol & Gene Therapy, E-31080 Pamplona, Spain
[2] CIC bioGUNE, Bizkaia, Spain
[3] DIGNA Biotech, Madrid, Spain
[4] Univ Navarra, Ctr Appl Med Res, Div Cardiovasc Sci, Lab Thrombosis & Haemostasis, E-31080 Pamplona, Spain
关键词
transforming growth factor beta 1; inhibitor peptides; phage display; liver; fibrosis;
D O I
10.1016/j.cyto.2007.06.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pathologies such as liver fibrosis and scleroderma are characterized by harmful levels of transforming growth factor beta 1 (TGF beta 1). These levels could be neutralized if inhibitors of this cytokine were available. With this aim we searched for peptides with binding affinity for TGF beta 1 using a phagp-displayed random 15-mer peptide library. Some peptides thus identified blocked activity of TGF beta 1 in vitro, as measured by their capacity to restore growth of Mv-1-Lu cells in presence of added TGF beta 1. Also, they inhibited TGF beta 1-dependent expression of collagen type I mRNA in liver of mice orally insulted with CC14. Intraperitoneal administration of 50 mu g of peptide P17 (the most active 15-mer peptide, also referred to as P17(1-15)) inhibited expression of collagen type I mRNA by almost 100%. Interestingly, titration experiments showed that P17(1-12) (a peptide encompassing the first 12 amino acids of P17) was approximately four times more active than P17. These results suggest that both peptides, as well as others reported here, may be of therapeutic interest in processes requiring control of undesired high levels of TGF beta 1. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:106 / 115
页数:10
相关论文
共 33 条
[1]  
AKHURST R J, 1990, Progress in Growth Factor Research, V2, P153, DOI 10.1016/0955-2235(90)90002-2
[2]  
Akhurst RJ, 2006, CURR OPIN INVEST DR, V7, P513
[3]   Adenoviral expression of a transforming growth factor-β1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats -: art. no. 29 [J].
Arias, M ;
Sauer-Lehnen, S ;
Treptau, J ;
Janoschek, N ;
Theuerkauf, I ;
Buettner, R ;
Gressner, AM ;
Weiskirchen, R .
BMC GASTROENTEROLOGY, 2003, 3 (1)
[4]  
Atherton E, 1989, J CHEM SOC PERKING T, V1, P538
[5]   Mechanisms of disease:: Role of transforming growth factor β in human disease. [J].
Blobe, GC ;
Schiemann, WP ;
Lodish, HF .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (18) :1350-1358
[6]   INSIGHTS ON THE AMINO-ACID SIDE-CHAIN INTERACTIONS OF A SYNTHETIC T-CELL DETERMINANT [J].
BORRASCUESTA, F ;
GOLVANO, J ;
SAROBE, P ;
LASARTE, JJ ;
PRIETO, I ;
SZABO, A ;
GUILLAUME, JL ;
GUILLET, JG .
BIOLOGICALS, 1991, 19 (03) :187-190
[7]  
BRENNER DA, 1993, HEPATOLOGY, V17, P287, DOI 10.1016/0270-9139(93)90090-A
[8]   TRANSFORMING GROWTH FACTOR-BETA-1 AND FACTOR-ALPHA IN CHRONIC LIVER-DISEASE - EFFECTS OF INTERFERON ALFA THERAPY [J].
CASTILLA, A ;
PRIETO, J ;
FAUSTO, N .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (14) :933-940
[9]   Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis [J].
CastillaCortazar, I ;
Garcia, M ;
Muguerza, B ;
Quiroga, J ;
Perez, R ;
Santidrian, S ;
Prieto, J .
GASTROENTEROLOGY, 1997, 113 (05) :1682-1691
[10]   INVITRO AND INVIVO ASSOCIATION OF TRANSFORMING GROWTH FACTOR-BETA-1 WITH HEPATIC-FIBROSIS [J].
CZAJA, MJ ;
WEINER, FR ;
FLANDERS, KC ;
GIAMBRONE, MA ;
WIND, R ;
BIEMPICA, L ;
ZERN, MA .
JOURNAL OF CELL BIOLOGY, 1989, 108 (06) :2477-2482